Cytori (CYTX) Stock: Positive Study Results… Time To Invest?

0

Cytori Therapeutics Inc (NASDAQ: CYTX)

Cytori is likely to have a good day in the market today. Early this morning, the company announced the publication of results from a Phase 1 clinical trial with regard to an erectile dysfunction treatment. Today, we’ll talk about the details that were released, take a look at how the market reacted to the news, and discuss what we can expect to see from CYTX moving forward.

Trade smarter and make more money with Tradespoon!

CYTX Releases Positive Phase 1 Data

Last year, CYTX started an investigator-initiated Phase 1 clinical trial with regard to Cytori Cell Therapy. The goal of the therapy is to prove that it is an effective treatment for erectile dysfunction following radical prostatectomy. The study included 17 patients that had undergone radical prostatectomy within 5 to 18 months before the study and had not regained erectile function following the surgery. According to the release, none of the 17 patients displayed any adverse events associated with the Cytori Cell Therapy. Also, 8 of the 17 patients had regained erectile function within three months of receiving the treatment. In a statement, Dr. Martha Haahr, lead investigator in the CYTX study had the following to say about the results:

We are very pleased with the results from our Phase 1 study. In this open-label trial, we saw a very good effect on erectile function. It is remarkable, especially as these men had previously seen no effect from traditional medical treatment and continue to have good erectile function after 6 months follow-up. This suggests the possibility of therapeutic options for patients suffering from erectile dysfunction from other causes. We are already planning a double-blind randomized follow-up study.”

How The Market Reacted To The News

Investors have learned over the years that the news moves the market. Any time we see positive news with regard to a publicly traded company, we can expect to see gains in the value of the stock. So naturally, with the positive study results in mind, investors are excited about what they can expect to see and we are seeing gains on the stock as a result. Currently (10:13), CYTX is trading at $0.19 per share after a gain of 4% so far today.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see overwhelmingly positive movement out of CYTX. The reality is that the company is heading in the right direction with regard to the creation of a much needed treatment. Currently, there is a large number of reasons that erectile dysfunction happens, and it was previously believed that correction of the ailment is not something that could happen on a pharmaceutical level. The news study results released by CYTX show the exact opposite. The company has shown in a small sample size that Cytori Cell Therapy has the ability to improve erectile function with no severe adverse effects. I’m also impressed with the concept that a double-blind randomized follow-up study is already being planned. After all, the Phase 1 study shows proof of concept, however’ a sample size of only 17 patients is incredibly small. So, it will be interesting to see how the upcoming Phase 2 study goes. All in all, I’m impressed with the results, and based on the reaction in the market, other investors are as well. With a clear plan outlined, I’m expecting to see further positive movement out of CYTX.

Don’t waste your time! Click here to find winning trades in minutes!

What Do You Think?

Where do you think CYTX is headed moving forward? Let us know your opinion in the comments below!

Previous articleFacebook (FB) Stock: This One’s Headed Up!
Next articleMannKind (MNKD) Stock: This One’s Going To Climb!
Hey, Im Joshua, the founder of CNA Finance. I enjoy following the trends in the market and finding the catalysts that are making the moves. If you want to get in contact with me, leave a comment below or email me at CNAFinanceHelp@gmail.com Please keep in mind that I am not an investment advisor and nor is CNA Finance. This is a news and information gathering outlet. We may work directly with some of the companies that we write about. If we have a business relationship with an issuer, we will mention that in the articles. We also have various affiliate relationships with advertisers and may be paid if you sign up for a service that you were referred to through our website.

LEAVE A REPLY

Please enter your comment!
Please enter your name here